|1.||Forst, Thomas: 19 articles (01/2012 - 10/2005)|
|2.||Pfützner, Andreas: 19 articles (01/2012 - 10/2005)|
|3.||Perez, Alfonso: 14 articles (07/2015 - 01/2004)|
|4.||Derosa, Giuseppe: 13 articles (09/2013 - 05/2004)|
|5.||Erdmann, Erland: 13 articles (01/2013 - 10/2005)|
|6.||DeFronzo, Ralph A: 12 articles (10/2014 - 06/2002)|
|7.||Henry, Robert R: 12 articles (07/2014 - 01/2003)|
|8.||Heneka, Michael T: 11 articles (08/2015 - 06/2002)|
|9.||Rasouli, Neda: 11 articles (01/2014 - 05/2005)|
|10.||Glintborg, Dorte: 11 articles (12/2012 - 10/2005)|
08/01/2001 - "Pioglitazone significantly (P < 0.001) decreased insulin resistance (HOMA-IR; -12.4+/-7.46%) and improved beta-cell function (Homeostasis Model Assessment (HOMA-BCF); +47.7+/-11.58%). "
01/01/2013 - "Pioglitazone is an oral antidiabetic agent effective for reactive hypoglycaemia and aggravated glycaemic metabolism associated with insulin resistance. "
01/01/2010 - "Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. "
03/01/2007 - "Pioglitazone is widely used for the treatment of diabetic patients with insulin resistance. "
10/01/2002 - "Pioglitazone has been shown to be effective and well tolerated in the treatment of patients with type 2 diabetes, as it reduces insulin resistance and improves glycaemic control and abnormal lipid profiles. "
|2.||Type 2 Diabetes Mellitus (MODY)
01/01/2013 - "Peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone previously used to treat type 2 diabetes mellitus (T2DM) has also been demonstrated to be effective in anti-inflammatory reaction and anti-oxidative stress in the animal models of AD and other neuroinflammatory diseases. "
01/01/2013 - "Pioglitazone is a PPARγ agonist that is widely used for the treatment of type 2 diabetes mellitus. "
09/01/2000 - "These data suggest pioglitazone to be effective in reducing UAE and urinary ET-1 concentrations in NIDDM patients with microalbuminuria."
10/01/2011 - "The renal and cerebral protective effects of pioglitazone were assessed in normoalbuminuric patients with type 2 diabetes mellitus (DM). "
10/01/2007 - "The aim of this study is to explore appropriate indicators for the efficacy of pioglitazone (Pio) before and during treatment of Japanese patients with type 2 diabetes mellitus (T2DM). "
12/01/2012 - "Patients treated with pioglitazone had significant improvement in lobular inflammation, portal inflammation and Brunts grade. "
12/01/2006 - "Pioglitazone significantly increased the number and improved the functional properties of EPCs in type II diabetic patients through direct effects and/or anti-inflammation and lipid modification effects."
04/01/2011 - "Pioglitazone is particularly effective for improving the manifestations of diabetic dyslipidaemia, in addition to its favorable effects on systemic inflammation and hyperglycaemia. "
09/01/2015 - "The aim of this study was to explore the effects of pioglitazone (Pio), a drug that induces release of inflammatory mediators, on cytokine and chemokine secretion in astrocytes stimulated with lipopolysaccharide (LPS) to induce inflammation. "
12/01/2008 - "The current study determines whether pioglitazone (PIO) therapy reduces both monocyte and lymphocyte inflammatory activity and their ability to induce inflammation in other tissues. "
|4.||Body Weight (Weight, Body)
08/01/2010 - "Pioglitazone (10, 20 and 40mg/kg, p.o.) treatment significantly improved body weight and motor functions, oxidative defense. "
11/01/2014 - "In this study, we observed a reversal of body weight gain but no recoveries in red blood cells or haematocrit or haemoglobin levels after stopping pioglitazone for 10 months in patients treated with pioglitazone for 38 months. "
01/01/2007 - "The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight."
01/01/2005 - "Body weight and fat increased steadily in the patients treated with pioglitazone during the 6 months of the study (+3.9 +/- 3.1 kg at 6 months in pioglitazone-treated patients vs -0.8 +/- 3.4 kg in the placebo-treated patients). "
01/20/2015 - "Pioglitazone increased body weight and food intake in DS/obese rats. "
01/01/2012 - "When pioglitazone (n = 137) was analysed alone, the improvement in fibrosis with pioglitazone (n = 137) vs. placebo (n = 134) (combined OR 1.68 [95% CI, 1.02-2.77]) was statistically significant. "
07/01/2006 - "In rats, the therapeutic antifibrotic efficacy of pioglitazone is limited and dependent on the type of injury, duration of disease, and/or the severity of fibrosis at the time of initiation of treatment."
07/01/2006 - "Therapeutic efficacy was assessed by comparison of the severity of hepatic fibrosis in pioglitazone treated versus untreated fibrotic controls. "
07/01/2006 - "Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats."
04/01/2012 - "For patients not responding to lifestyle intervention, pioglitazone improves histological disease activity, slows fibrosis progression and extensively ameliorates cardio-metabolic endpoints. "
|9.||Peroxisome Proliferator-Activated Receptors (PPAR)
|10.||Blood Glucose (Blood Sugar)
|1.||Renal Dialysis (Hemodialysis)
|2.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)